Go to the list of all blogs
Niko Sharks's Avatar
published in Blogs
Dec 10, 2023
Installation Industry Stocks($NBIX, $ACAD, $ALKS, $MDXG, $CYCCP...) Surge with an Average 19.6% Monthly GainšŸ“ˆ

Installation Industry Stocks($NBIX, $ACAD, $ALKS, $MDXG, $CYCCP...) Surge with an Average 19.6% Monthly GainšŸ“ˆ

The installation industry, particularly in the residential segment, has seen a remarkable surge in stock performance over the past month. Companies operating in this sector, such as Masco Corp. (MAS), Installed Building Products Inc. (FIX), and nVent Electric plc. (NVT), have all contributed to this impressive performance.

🌐Tickers in Industry - $NBIX, $ACAD, $ALKS, $MDXG, $CYCCP, $VCEL, $VTGN, $MRNA 

Choppy Market Trader, Popular Stocks: Market Neutral Strategy (TA&FA)Ā -Ā Annualized Return + 107%

Theme and Group of Tickers Inside the Theme

The theme in focus here is the installation industry, with a specific emphasis on companies engaged in manufacturing home products and items related to home improvement. The notable tickers within this theme include:

  1. Masco Corp. (MAS): Specializes in building and home improvement products.
  2. Installed Building Products Inc. (FIX): Primarily involved in insulation installer operations.
  3. nVent Electric plc. (NVT): Specializes in electrical connections.

Market Cap

The average market capitalization for companies within the installation theme is approximately $5.6 billion. However, there is significant variation within this group, with market caps ranging from $52.3 million to $13.4 billion. Masco Corp. (MAS) holds the highest valuation at $13.4 billion, while the lowest valued company is KEQU at $52.3 million.

High and Low Price Notable News

In the past month, stocks within the installation theme have experienced substantial price movements. On average, these stocks have seen a remarkable monthly price growth of 19.6%. The average weekly price growth was 6.44%, and the average quarterly price growth was 25.83%.

Notable price movements in this theme include Masco Corp. (MAS) witnessing a significant weekly decline of -5.16% and, in contrast, a weekly gain of +5.43%. nVent Electric (NVT) also saw a notable weekly gain of +5.79%, reflecting the volatility and potential for substantial returns in this sector.

Volume

The trading volumes for stocks in the installation theme have exhibited some interesting trends. On average, there was a weekly volume decrease of -4.76% in the past month, while the monthly and quarterly volume trends showed even more significant declines of -34.01% and -16.5%, respectively.

It's worth noting that nVent Electric's stock witnessed a remarkable daily volume growth of 99% of the 65-Day Volume Moving Average on August 1, 2023. Similarly, Griffon stock experienced a one-day volume surge, reaching a growth of 296% of the 65-Day Volume Moving Average on June 17, 2023.

Fundamental Analysis Ratings

While specific fundamental analysis ratings are not provided in the information given, it's clear that the installation industry, particularly in the residential segment, is exhibiting strong performance. The impressive monthly price growth of 19.6% underscores the sector's potential for investors seeking growth opportunities.

The installation industry, encompassing companies involved in home improvement and related products, has shown outstanding stock performance over the past month. Investors should take note of the opportunities presented by stocks like Masco Corp. (MAS), Installed Building Products Inc. (FIX), and nVent Electric plc. (NVT) in this thriving sector.

NBIXĀ :Ā On November 24, 2023, NBIX exhibited a noteworthy shift in its trajectory as it crossed above its 50-day Moving Average. Historically, such occurrences have often translated into positive momentum, with 32 out of 39 comparable instances resulting in subsequent price increases over the following month. With an 82% probability, the odds appear favorable for NBIX to sustain its upward trajectory. Investors may find this development an encouraging sign for potential gains in the near future.

ACADĀ :Ā ACAD Pharmaceuticals recently exhibited a notable shift in its stock trajectory, breaching its 50-day Moving Average on December 5, 2023. This movement signifies a potential reversal from its previous upward momentum to a bearish trend. Historical analysis reveals that in 35 out of 45 comparable scenarios, ACAD's stock experienced further decline in the subsequent month. This pattern suggests a 78% probability of the stock continuing its downward trend. Investors and market analysts are closely monitoring this development, considering its implications for future investment strategies and market positioning related to ACAD.

ALKSĀ :Ā ALKS Pharmaceuticals exhibited a significant shift in market sentiment as its Momentum Indicator ascended above the zero mark on November 16, 2023. This transition is widely interpreted as a precursor to a new upward trend in the stock's performance. Investors and traders are advised to consider strategies like purchasing shares or opting for call options in anticipation of potential gains. Tickeron's A.I.dvisor analyzed 95 comparable events where the indicator turned positive. In 76 of these instances, ALKS's stock price increased in the subsequent period, indicating an 80% likelihood of a continued upward movement. This trend presents a promising opportunity for market participants focusing on ALKS.

Ā 

Related Ticker: NBIX, ACAD, ALKS, MDXG, BGMSP, VCEL, VTGN, MRNA

Momentum Indicator for NBIX turns positive, indicating new upward trend

NBIX saw its Momentum Indicator move above the 0 level on October 05, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 87 similar instances where the indicator turned positive. In 64 of the 87 cases, the stock moved higher in the following days. The odds of a move higher are at 74%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NBIX's RSI Indicator exited the oversold zone, 19 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 63%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 38 of 58 cases where NBIX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 66%.

The Moving Average Convergence Divergence (MACD) for NBIX just turned positive on October 02, 2026. Looking at past instances where NBIX's MACD turned positive, the stock continued to rise in 37 of 54 cases over the following month. The odds of a continued upward trend are 69%.

Following a +2.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where NBIX advanced for three days, in 223 of 316 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.

NBIX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NBIX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 54%.

The Aroon Indicator for NBIX entered a downward trend on October 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 44 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 56 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock slightly better than average.

The Tickeron Valuation Rating of 57 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.865) is normal, around the industry mean (43.873). P/E Ratio (20.529) is within average values for comparable stocks, (141.710). Projected Growth (PEG Ratio) (0.280) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (4.587) is also within normal values, averaging (178.797).

The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating fairly steady price growth. NBIX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 91 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), BioCryst Pharmaceuticals (NASDAQ:BCRX), Tilray Brands Inc. (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.13B. The market cap for tickers in the group ranges from 2.12K to 68.49B. MKGAF holds the highest valuation in this group at 68.49B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -6%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was 27%. RGC experienced the highest price growth at 17%, while LQDA experienced the biggest fall at -62%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was 44%. For the same stocks of the Industry, the average monthly volume growth was 55% and the average quarterly volume growth was 1%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 51
P/E Growth Rating: 63
Price Growth Rating: 58
SMR Rating: 86
Profit Risk Rating: 84
Seasonality Score: 1 (-100 ... +100)
View a ticker or compare two or three
NBIX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a product based biopharmaceutical company

Industry PharmaceuticalsGeneric

Industry
Biotechnology
Address
6027 Edgewood Bend Court
Phone
+1 858 617-7600
Employees
2000
Web
https://www.neurocrine.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
GE Aerospace (GE) stock declined -12% over the past 30 days, falling from around $333 to $293, amid profit-taking after record highs near $348. Over the past quarter, the stock is down -8%, reflecting post-earnings selloff despite strong Q4 2025 results with 20% revenue growth.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
Sable Offshore Corp. (SOC) shares fell 7.40% in the most recent completed session, closing at $16.52 versus a prior close of $17.84. The pullback followed a volatile stretch in which SOC traded between $15.76 and $19.21 over just two sessions, reflecting profit‑taking after a strong run in March.
NBR stock rose approximately +12% over the last 30 days, driven by positive momentum in the oil and gas drilling sector and strong Q4 earnings beat. Over the past quarter, the stock surged +58%, fueled by robust YTD performance, debt reduction efforts, and improved operational results in international drilling.
Patterson-UTI Energy, Inc. (PTEN) stands out as a leading provider of drilling and completion services to oil and natural gas exploration and production companies, primarily in the United States and select international markets. The company operates through three main segments: Drilling Services, which includes contract drilling rigs and directional drilling; Completion Services, encompassing hydraulic fracturing, wireline, and pumping; and Drilling Products, offering specialized drill bits globally, including in the Middle East.
As a provider of onshore drilling and completion services, Patterson-UTI Energy (PTEN) is gearing up for a key Q1 2026 earnings report against the backdrop of fluctuating oil prices and steady U.S. rig demand. The company's integrated approach across Drilling Services, Completion Services, and Drilling Products gives it a solid footing in North American shale plays. In my view, recent quarters like Q4 2025, where revenue exceeded estimates despite a net loss, highlight its resilience. This upcoming report will offer insights into activity levels, margin trends, and capital discipline amid supply growth and geopolitical tensions. With strong free cash flow and recent dividend increases, PTEN's focus on shareholders stands out, making this a critical gauge for the 2026 outlook in the cyclical oilfield services sector.
When geopolitical turmoil sends markets into chaos, most retail traders freeze — but Tickeron's Energy (OXY, EOG, DVN, FANG, APA, MTDR) AI Trading Agent is built to thrive in exactly these conditions. This 15-minute and 60-minute AI-powered robot has delivered a +76.22% annualized return with a 64.21% win rate and a Profit Factor of 2.70 — trading six of the most volatile and opportunity-rich energy tickers on the market.
The global energy sector is on fire — literally and figuratively. With crude oil prices swinging 20–30% in response to geopolitical flashpoints, OPEC+ production cuts, and escalating conflicts in Eastern Europe and the Middle East, traders who aren't using AI-powered tools are flying blind. Enter Tickeron's Energy (Oil & Gas – E&P) AI Trading Agent — a 60-minute signal robot built exclusively around five high-impact Exploration & Production tickers, now posting a staggering +49% Annualized Return and +1,251% 30-Day Annualized Return, with $14,703 in closed-trade P&L on a $30,000 simulated balance.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
Installation Industry Stocks($NBIX, $ACAD, $ALKS, $MDXG, $CYCCP...) Surge with an Average 19.6% Monthly GainšŸ“ˆ